John Vest

SVP at Alnylam Pharmaceuticals

Speaker

Dr. John Vest joined Alnylam in 2015 and is currently Senior Vice President, TTR Global Clinical Lead. In this role Dr. Vest oversees both the clinical development strategy and clinical trial execution for Alnylam’s innovative RNAi therapeutics targeting transthyretin. He has played an instrumental role in the development, including multiple pivotal Phase 3 studies, of ONPATTRO and AMVUTTRA as well as the ongoing development of nucresiran. Before joining Alnylam, he worked in the Cardiovascular Translational Medicine group at Novartis where he played a key clinical role in developing the company’s early-stage pipeline of compounds in the cardiovascular space. Prior to his career in industry, Dr. Vest spent over 16 years in the study and practice of medicine. Dr. Vest received his MD from Columbia University where he went on to complete a residency in Internal Medicine and fellowship in Cardiovascular Disease. He subsequently completed sub-specialty training in Clinical Cardiac Electrophysiology at the Brigham and Women’s Hospital before returning to Columbia where he joined the faculty of the Cardiology Division.